Clinical Trials Logo

Acute Graft Versus Host Disease clinical trials

View clinical trials related to Acute Graft Versus Host Disease.

Filter by:

NCT ID: NCT02241018 Recruiting - Clinical trials for Acute Graft-versus-host Disease

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

NCT ID: NCT02044185 Recruiting - Clinical trials for Acute Graft-versus-host Disease

Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation

CHIP-SCT
Start date: January 2014
Phase: N/A
Study type: Observational

Acute Graft-versus-host disease(aGVDH) after allogeneic hematopoietic stem cell transplantation is one of the meaningful issues in aspect of patient's recovery and survival. in recent years, the understanding of the pathology of GVHD is much important to prevent or treat aGVHD. additionally, (oral) mucositis is one of the problems in patients with high dose chemotherapy, and mucositis by high-dose chemotherapy is related to HMGB-1 as proinflamtory cytokines. HMGB1 is a nuclear protein acts as a transcription factor, but, if it was released to the outside of cells by damaged cell or necrotic tissues, it works as cytokines for promoter of inflammation and cancers. at this point, there are no reported articles about correlation of HMGB1 and aGVHD in human. recently, we have seen excessive secretion of serum HMGB1 in mouse model, then base on this results, we will check correlation of HMGB1 and aGVHD/ oral mucositis in human.

NCT ID: NCT01765634 Recruiting - Clinical trials for Acute Graft-versus-host Disease

Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the utility of treating patients experiencing refractory acute graft-versus-host disease with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. The objective was to evaluate the effect and safety of such treatment on refractory acute graft-versus-host disease.

NCT ID: NCT01521039 Recruiting - Clinical trials for Acute Graft-versus-Host Disease

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

Start date: February 20, 2012
Phase:
Study type: Observational

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (GVHD).